The authors of a recent study published in JAMA suggest that less than five percent of state laws passed in the last few years will have much impact on boosting drug pricing transparency, FiercePharma reports.
Neeraj Sood, one of the study’s authors, tells FiercePharma the laws fall short of bringing more attention to the current drug pipeline.
“These laws are really not truly making the system more transparent,” Sood said. “They’re really not helping us tell whose story is right—are the pharma companies right or are the wholesalers right or are the PBMs right? Look, it’s good that there’s some activity going on, but we haven’t solved the problem even with all these laws.”
To read the full report on FiercePharma, click here.